Showing results (41-50 of 53) with videos related to
Sort By:
Pageof 6
Advances in Therapy|August 11, 2017
Health-Related Quality of Life in Individuals with Down Syndrome: Results from a Non-Interventional Longitudinal Multi-National StudyDiana Rofail, Daniel Froggatt, Rafael de la Torre, et al.Neurology and Therapy|September 25, 2023
Experience of Daily Life with Generalized Myasthenia Gravis: A Qualitative Investigation and Assessment of Instrument Content ValidityChristopher A Hartford, Steven A Sherman, Stella Karantzoulis, et al.BMJ Open|January 17, 2024
Thematic analysis to explore patients' experiences with long COVID-19: a conceptual model of symptoms and impacts on daily livesDiana Rofail, Selin Somersan-Karakaya, Julia Y Choi, et al.Acta Haematologica|April 29, 2010
Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR TrialAli Taher, Abdullah Al Jefri, Mohsen Saleh Elalfy, et al.Journal of Patient-Reported Outcomes|August 8, 2024
The symptoms evolution of long COVID‑19 (SE-LC19): a new patient-reported content valid instrumentDiana Rofail, Selin Somersan-Karakaya, Eleftherios Mylonakis, et al.Anemia|August 28, 2012
Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical TrialJohn Porter, Donald K Bowden, Marina Economou, et al.Current Medical Research and Opinion|May 30, 2008
Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA studyLuciana Scalone, Lorenzo G Mantovani, Marieke Krol, et al.Ejhaem|July 25, 2025
Safety, Efficacy, and Patient-Reported Outcomes From a Phase 2 Randomized Trial of Pozelimab and Cemdisiran Combination in Patients With Paroxysmal Nocturnal HemoglobinuriaJun-Ho Jang, Raymond Siu Ming Wong, Christopher Hartford, et al.Scientific Reports|August 7, 2023
Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profilesDateng Li, Meng Xu, Andrea T Hooper, et al.Acta Haematologica|April 15, 2008
Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trialElliott Vichinsky, Zahra Pakbaz, Onyinye Onyekwere, et al.Pageof 6